Renovaro Beheer

Beheer criteriumcontroles 1/4

De CEO Renovaro is David Weinstein, benoemd in Oct2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.16% van de aandelen van het bedrijf, ter waarde € 123.34K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 3.3 jaar.

Belangrijke informatie

David Weinstein

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

CEO

David Weinstein (64 yo)

less than a year

Tenure

Mr. David H. Weinstein, also known as David, is CEO & Director of Renovaro Inc. from October 14, 2024. Mr. Weinstein has extensive experience with U.S. securities and investment banking firms. He has been...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Simon Tarsh	Interim Chief Financial Officer	less than a year	US$330.33k	geen gegevens
Francois Binette	COO and Executive VP for Research & Development	2yrs	US$430.29k	0% € 0
David Weinstein	CEO & Director	less than a year	geen gegevens	0.16% € 123.3k
Serhat Gümrükcü	Co-Founder & Inventor	no data	geen gegevens	11.12% € 8.7m
Greg Duczynski	Senior Vice President for Clinical Operations	2.6yrs	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2Q5 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Weinstein	CEO & Director	less than a year	geen gegevens	0.16% € 123.3k
James McNulty	Independent Director	less than a year	geen gegevens	geen gegevens
Richard Whitley	Member of Respiratory Diseases Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Anna Lok	Member of HBV Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Carol Brosgart	Chairperson of HBV Cure Scientific Advisory Board	4.3yrs	US$129.74k	0% € 0
Fabien Zoulim	Member of HBV Scientific Advisory Board	4.3yrs	geen gegevens	geen gegevens
Maurice Van Tilburg	Independent Director	less than a year	geen gegevens	geen gegevens
Mark Collins	Independent Director	less than a year	geen gegevens	geen gegevens
W. Hardy	Chairman of HIV Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
Steven Deeks	Member of HIV Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Peter Revill	Member of HBV Scientific Advisory Board	4.3yrs	geen gegevens	geen gegevens
Geert Kazemier	Chairman of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

72yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2Q5 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Renovaro Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Renovaro Inc. Announces CEO Changes

Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board

Renovaro Inc. Announces Board Changes

Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors

Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors

Enochian Biosciences Inc., Annual General Meeting, Jun 22, 2023

Recent updates

Renovaro Inc. Announces CEO Changes

Renovaro Inc. announced delayed annual 10-K filing

Renovaro Receives Deficiency Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board

Renovaro Inc. Announces Board Changes

Renovaro Biosciences Inc. (NasdaqCM:RENB) completed the acquisition of GEDi Cube Intl Ltd.

Renovaro Biosciences Inc. contemplates bankruptcy.

Renovaro Biosciences Inc. contemplates bankruptcy.

Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors

Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors

Renovaro Biosciences Inc. announced delayed annual 10-K filing

Renovaro Biosciences Inc. (NasdaqCM:RENB) signed a letter-of-intent to acquire GEDi Cube Intl Ltd.

Enochian Biosciences Inc. Receives Non-Compliance Letter from Nasdaq

Enochian Biosciences Inc.(NasdaqCM:ENOB) dropped from Russell Small Cap Comp Value Index

Enochian Biosciences Inc. Announces That Its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

Enochian Biosciences Inc., Annual General Meeting, Jun 22, 2023

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for Period Ended September 30, 2022

Enochian Biosciences, Inc. announced delayed 10-Q filing

Enochian Biosciences Receives Notice from Nasdaq for Not Filing Form 10-K

Enochian Biosciences, Inc. announced delayed annual 10-K filing

Rosen Law Firm Encourages Enochian Biosciences Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action

Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Enochian Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Enochian Biosciences, Inc

Johnson Fistel, LLP Announces That A Class Action Lawsuit Commence on Behalf of Investors of Enochian Biosciences Inc

High number of new and inexperienced directors

High number of new directors

Enochian BioSciences Appoints Dr. François Binette, Ph.D. as Executive Vice President for Research and Development

Enochian Biosciences, Inc. Announces Appointment of Greg Duczynski as Senior Vice President for Clinical Operations

High number of new directors

Enochian Biosciences, Inc. Announces Resignation of Carl Sandler as Member of the Board of Directors

Enochian Biosciences, Inc., Annual General Meeting, Mar 14, 2022

High number of new directors

High number of new directors

Enochian Biosciences, Inc. Announces Its Successful Completion of FDA Pre-IND for A Potential Cure for Hepatitis B Virus Infection

High number of new directors

High number of new directors

High number of new directors

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

Enochian Biosciences, Inc.(NasdaqCM:ENOB) dropped from Russell 3000E Value Index

Enochian BioSciences, Inc. Announces FDA Acceptance of Pre-IND Request for Potential HIV Cure

New 90-day high: €3.74

Enochian Biosciences, Inc., Annual General Meeting, Mar 05, 2021

New 90-day high: €2.80

New 90-day low: €2.48

New 90-day low: €2.58

New 90-day low: €2.78

New 90-day low: €2.98

New 90-day low - €3.00

Enochian Biosciences, Inc.(NasdaqCM:ENOB) dropped from Russell 3000 Growth Index

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd